Intravenous or subcutaneous natalizumab in patients with relapsing–remitting multiple sclerosis: investigation on efficiency and savings—the EASIER study

Massimo Filippi; Luigi Grimaldi; Antonella Conte; Rocco Totaro; Maria Rosaria Valente; Simona Malucchi; Franco Granella; Cinzia Cordioli; Vincenzo Brescia Morra; Chiara Zanetta; Daria Perini; Laura Santoni; Vanessa Ziccone; R. Garba; A. Motta; S. Albanesi; O. Oddo; A. Impagliato; Gina Ferrazzano; V. Di Rosa; Maria Carmela Tartaglia; Anna Di Vito; Alfredo R. Galassi; Roberto Prota; Roberto Garbo; Ilaria Del Negro; L. Nesi; Marco Capobianco; Elena Tsantes; R. Agosta; A. M. Valleri; L. Galuppini; Santa Mascara; F. Bertocchi; Emanuela Chiarini; Marcello Moccia; Giorgia Puorro

doi:10.1007/s00415-023-11955-0

Back

Shared by

Massimo Filippi

Intravenous or subcutaneous natalizumab in patients with relapsing–remitting multiple sclerosis: investigation on efficiency and savings—the EASIER study

Article 2023 en

Authors

Massimo Filippi
LG
Luigi Grimaldi
AC
Antonella Conte

Abstract

1 min read

SC natalizumab administration will consistently reduce consumption of patient and HCP times per procedure and associated costs.

Related publications

Article2018

086 The rapid efficacy of natalizumab vs fingolimod in patients with active relapsing-remitting multiple sclerosis (RRMS): results from reveal, a randomised, head-to-head study

Helmut Butzkueven, Douglas Jeffery, Douglas L. Arnold, Massimo Filippi, Jeroen J.G. Geurts, Qunming Dong, Nolan Campbell, Stephanie Licata, Pei‐Ran Ho

Article2015

The Effects of Natalizumab and Fingolimod on Clinical, Neuropsychological and MRI Measures in Relapsing Remitting Multiple Sclerosis: A One-Year Comparative Study (P6.152)

Paolo Preziosa, Maria A. Rocca, Gianna Carla Riccitelli, Mariaemma Rodegher, Massimiliano Copetti, Lucia Moiola, Francesco Mele, Andrea Falini, Giancarlo Comi, Massimo Filippi

Article2022

EE43 Subcutaneous or Intravascular Route of Administration for Natalizumab in Relapsing Remitting Multiple Sclerosis: Economic Appraisal of the Easier Study

Massimo Filippi, Luigi Maria Edoardo Grimaldi, Adriano Mosca Conte, Rocco Totaro, MR Valente, S. Malucchi, Franco Granella, Cinzia Cordioli, Vincenzo Brescia Morra, Daria Perini, L Santoni

Article2017

The Effects of Natalizumab and Fingolimod on Clinical and MRI Measures in Relapsing Remitting Multiple Sclerosis: A Two-Year Comparative Study (P2.073)

Paolo Preziosa, Maria A. Rocca, Gianna Carla Riccitelli, Mariaemma Rodegher, Lucia Moiola, Andrea Falini, Giancarlo Comi, Massimo Filippi

Article2020

Effects of Fingolimod and Natalizumab on Slowly Expanding Lesion Occurrence over Two Years of Treatment in Relapsing-remitting Multiple Sclerosis (1317)

Paolo Preziosa, Elisabetta Pagani, Lucia Moiola, Mariaemma Rodegher, Massimo Filippi, Maria A. Rocca

Intravenous or subcutaneous natalizumab in patients with relapsing–remitting multiple sclerosis: investigation on efficiency and savings—the EASIER study

Abstract

Discussion(0)

Related publications

086 The rapid efficacy of natalizumab vs fingolimod in patients with active relapsing-remitting multiple sclerosis (RRMS): results from reveal, a randomised, head-to-head study

The Effects of Natalizumab and Fingolimod on Clinical, Neuropsychological and MRI Measures in Relapsing Remitting Multiple Sclerosis: A One-Year Comparative Study (P6.152)

EE43 Subcutaneous or Intravascular Route of Administration for Natalizumab in Relapsing Remitting Multiple Sclerosis: Economic Appraisal of the Easier Study

The Effects of Natalizumab and Fingolimod on Clinical and MRI Measures in Relapsing Remitting Multiple Sclerosis: A Two-Year Comparative Study (P2.073)

Effects of Fingolimod and Natalizumab on Slowly Expanding Lesion Occurrence over Two Years of Treatment in Relapsing-remitting Multiple Sclerosis (1317)